Transcode Therapeutics, Inc. (RNAZ): Depreciation & Amortization
$76.4K
Year ended 2025-12-31
$97.4K
Trailing 12 months to 2026-06-30
-8.1%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $76.4K | -15.9% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $90.9K | -26.4% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $123.5K | +25.2% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $98.6K | +132.2% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $42.5K | n/a | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2022-03-31, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $76.4K | -15.9% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $2.48M | +60.2% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $97.0K | n/a |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $1.25M | +15.2% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $233.0K | -60.4% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $3.20M | -29.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $1.54M | -6.3% |
Compare RNAZ, ACRS, AQST, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗